Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral: Vanier Canada Graduate Scholarships

University of Toronto

$150,000.00

Validation and characterization of candidate familial pancreatic cancer genes.

FY 2009-10

Summary
Pancreatic cancer is the fourth-leading cause of cancer death in Canada, with poor prognosis even when resectable. Up to 10% of pancreatic cancer cases are hereditary, but the responsible genes in most of these cases remain unknown. A novel approach to identifying disease-associated genes is through analyzing genomic copy number variation (CNV). Recent research has demonstrated that the human genome has significant variability between individuals in the number of copies of different genomic regions; some individuals may carry more than the expected "two" copies of some genes, while others may have only one or even zero copies of some genes. Through up-to-date technology and computational analyses, our group was able to identify 244 CNV genomic regions in 120 high-risk pancreatic cancer patients. These regions are present in either a greater copy numbre (i.e. gains) or smaller copy number (i.e. deletions) in the cancer patients, relative to healthy individuals. Genes which fall in those CNV regions may become overexpressed (if affected by gains) or underexpressed (if affected by deletions) in the cancer patients. We propose that one or more of those genes that are differentially expressed in the cancer patients lead to the development of pancreatic cancer. A total of 621 genes fall in the 244 CNV regions, of which 55 are previously reported as cancer-associated, and seven of them have evidence for overexpression or underexpression in pancreatic cancer. We intend to investigate those genes, using various molecular techniques, to verify their potential involvement in the development of pancreatic cancer. Candidate genes will then be tested for mutations in all of our high-risk pancreatic cancer patients, to identify those mutations that may be inherited and increase the risk of cancer development.
Program
Doctoral: Vanier Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
197216
Name
Al-Sukhni Wigdan
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Vanier Canada Graduate Scholarships CIHR
Projecttitle
Validation and characterization of candidate familial pancreatic cancer genes.
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Cancer Genetics; Dna-Hybridization Microarrays; Genomic Copy Number Variation; Oncogenes; Pancreatic Cancer; Tumor Suppressor Genes
Abstract
Pancreatic cancer is the fourth-leading cause of cancer death in Canada, with poor prognosis even when resectable. Up to 10% of pancreatic cancer cases are hereditary, but the responsible genes in most of these cases remain unknown. A novel approach to identifying disease-associated genes is through analyzing genomic copy number variation (CNV). Recent research has demonstrated that the human genome has significant variability between individuals in the number of copies of different genomic regions; some individuals may carry more than the expected "two" copies of some genes, while others may have only one or even zero copies of some genes. Through up-to-date technology and computational analyses, our group was able to identify 244 CNV genomic regions in 120 high-risk pancreatic cancer patients. These regions are present in either a greater copy numbre (i.e. gains) or smaller copy number (i.e. deletions) in the cancer patients, relative to healthy individuals. Genes which fall in those CNV regions may become overexpressed (if affected by gains) or underexpressed (if affected by deletions) in the cancer patients. We propose that one or more of those genes that are differentially expressed in the cancer patients lead to the development of pancreatic cancer. A total of 621 genes fall in the 244 CNV regions, of which 55 are previously reported as cancer-associated, and seven of them have evidence for overexpression or underexpression in pancreatic cancer. We intend to investigate those genes, using various molecular techniques, to verify their potential involvement in the development of pancreatic cancer. Candidate genes will then be tested for mutations in all of our high-risk pancreatic cancer patients, to identify those mutations that may be inherited and increase the risk of cancer development.
Competitiondate
200911
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Al-Sukhni, Wigdan
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~